103420-77-5 Usage
Description
Devazepide, derived from asperlicin through chemical modification, is a cholecystokinin antagonist with a benzodiazepine backbone. It is an indolecarboxamide obtained by formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. Devazepide is known for its role in treating gastrointestinal disorders.
Uses
Used in Pharmaceutical Industry:
Devazepide is used as a cholecystokinin receptor 1 (CCK1R) antagonist for the treatment of gastrointestinal disorders. It has been utilized in human embryonic kidney 293T cells and human pancreatic slices to block the action of cholecystokinin, a hormone that stimulates the contraction of the gallbladder and the secretion of digestive enzymes.
Used in Research Applications:
In addition to its pharmaceutical applications, Devazepide is also used as an antagonist in research settings. It helps in studying the role of cholecystokinin and its receptors in various biological processes and disorders, contributing to a better understanding of the underlying mechanisms and potential therapeutic targets.
Biochem/physiol Actions
Devazepide is a CCK1 (CCK-A) receptor antagonist and a CCK8 antagonist.
Check Digit Verification of cas no
The CAS Registry Mumber 103420-77-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,4,2 and 0 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 103420-77:
(8*1)+(7*0)+(6*3)+(5*4)+(4*2)+(3*0)+(2*7)+(1*7)=75
75 % 10 = 5
So 103420-77-5 is a valid CAS Registry Number.
InChI:InChI=1/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1
103420-77-5Relevant articles and documents
An improved synthesis and resolution of 3-amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones
Sherrill,Sugg
, p. 730 - 734 (2007/10/02)
-
Methods for Drug Discovery: Development of Potent, Selective, Orally Effecive Cholecystokinin Antagonists
Evans, B. E.,Rittle, K. E.,Bock, M. G.,DiPardo, R. M.,Freidinger, R. M.,et al.
, p. 2235 - 2246 (2007/10/02)
3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines, antagonists of the peptide hormone cholecystokinin (CCK), are described.Developed by reasoned modification of the known anxiolytic benzodiazepines, these compounds provide highly potent, orally effective ligands selective for peripheral (CCK-A) receptors, with binding affinities approaching or equaling that of the natural ligand CCK-8.The distinction between CCK-A receptors on the one hand and CNS (CCK-B), gastrin, and central benzodiazepine receptors on the other is demonstrated by using the structure-activity profiles of the new compounds.Details of the binding of these agents to CCK-A receptors are examined, and the method of development of these compounds is discussed in terms of its relevance to the general problem of drug discovery.
